We learned from Novo Nordisk that on December 31, 2025, the Supreme People's Court handed down a favorable ruling on intellectual property related to the simeglutide compound patent, supporting the Beijing Intellectual Property Court's ruling on maintaining the validity of the simeglutide compound patent. Note that this does not affect the patent for the semeglutide compound expiring in 2026. Novo Nordisk said earlier that the patent for the simeglutide compound has expired in some markets of the International Operations Department and is expected to have a low single-digit negative impact on the company's global sales growth in 2026. This judgment did not change this expectation.

We learned from Novo Nordisk that on December 31, 2025, the Supreme People's Court handed down a favorable ruling on intellectual property related to the simeglutide compound patent, supporting the Beijing Intellectual Property Court's ruling on maintaining the validity of the simeglutide compound patent. Note that this does not affect the patent for the semeglutide compound expiring in 2026. Novo Nordisk said earlier that the patent for the simeglutide compound has expired in some markets of the International Operations Department and is expected to have a low single-digit negative impact on the company's global sales growth in 2026. This judgment did not change this expectation.